Cilengitide trifluoroacetate

For research use only. Not for use in humans.

目录号:S7077 别名: EMD 121974, NSC 707544 中文名称:三氟醋酸盐西仑吉肽

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide (EMD 121974, NSC 707544)是一种有效的integrin抑制剂,作用于αvβ3受体和αvβ5受体,无细胞试验中IC50分别为4.1 nM和79 nM,比作用于gpIIbIIIa选择性高10倍左右。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3718.02 现货
RMB 2212.59 现货
RMB 8108.38 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Cilengitide trifluoroacetate发表文献36篇:

产品安全说明书

Integrin抑制剂选择性比较

生物活性

产品描述 Cilengitide (EMD 121974, NSC 707544)是一种有效的integrin抑制剂,作用于αvβ3受体和αvβ5受体,无细胞试验中IC50分别为4.1 nM和79 nM,比作用于gpIIbIIIa选择性高10倍左右。Phase 2。
靶点
αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
体外研究

Cilengitide是一种环化五胜肽类肽,争夺精氨酸-甘氨酸-天冬氨酸(RGD)肽序列。调节整合素-配体结合。Cilengitide选择性且有效抑制αvβ3和αvβ5整合素与基质蛋白结合,如Vitronectin, Fibronectin, Fibrinogen, von Willebrand Factor, Osteopontin, 及其他。[1]10 μM Cilengitide完全抑制BAE,BME和HUVE细胞与Vitronectin 和 Fibronectin附着。Cilengitide在体外作用于三维胶原蛋白和血纤维蛋白凝胶使用FGF-2(或 VEGF-A)预处理的BAE细胞,抑制血管生成,IC50分别为15 μM 和8 μM, 4 μM 和 3 μM。[2]Cilengitide 抑制细胞增殖,诱导内皮细胞凋亡,且诱导人体内皮前体细胞分化。50 μg/mL Cilengitide完全抑制人体微血管内皮细胞系HMEC-1增殖,导致〜30%细胞发生细胞凋亡。[3]1 μM Cilengitide处理9天,抑制近40%EPCs增殖。1 μM Cilengitide处理14天,抑制80%以上EPCs 分化。[4]Cilengitide抑制粘附,诱导肿瘤细胞凋亡。25 μg/mL Cilengitide使60%以上的DAOY细胞(髓母细胞瘤)和U87MG细胞(胶质母细胞瘤) 与Vitronectin 和 Tenascin分离。25 μg/mL Cilengitide诱导细胞凋亡率将近50% 。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LN-308  MofkSpVv[3Srb36gRZN{[Xl? MXGxM|ExNzFyMPMAje69dQ>? MoPpNlQhcA>? MXLEUXNQyqB? NV73ZWRQemWmdXPld{BFWkVicnXwc5J1\XJiYXP0bZZqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NES2OHIzPjVyMEC1Oi=>
ZH-161 M1ryNWZ2dmO2aX;uJGF{e2G7 Mo\XNU8yOOLCid88cS=> MnLkNlQhcA>? NIH0eG9FVVORwrC= MV7y[YR2[2W|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=> NXLUV|QxOjZ3MECwOVY>
S-24 NIjzTZlHfW6ldHnvckBCe3OjeR?= M2LNNlEwOTEkgJpOwI0> NG\GU4gzPCCq M3zEZmROW00EoB?= NXryZ3I6emWmdXPld{BFWkVicnXwc5J1\XJiYXP0bZZqfHl? NXLwV|hEOjZ3MECwOVY>
HaCaT  MojZSpVv[3Srb36gRZN{[Xl? NGrqTIcyOOLCid88cS=> NFjiUIg1QCCq M1vXTGROW00EoB?= Mmr0doVlfWOnczDUS2Yu|rJ{wrDtVm5CKGW6cILld5Nqd25? M4XVc|I3PTByMEW2
LN-308  MUnGeY5kfGmxbjDBd5NigQ>? Ml;ZNVDjiIoQvH2= M1nlflI1KGh? Mnv2SG1UV8Li M4nQW5Jm\HWlZYOgRYhTKHC{b4TlbY4hdGW4ZXzzJIFv\CCGUlWgdoVxd3K2ZYKgZYN1cX[rdIm= NX6zZppoOjZ3MECwOVY>
REN Mn3HR4VtdCCYaXHibYxqfHliQYPzZZk> MXuxJI5ONTJyMDFOwG0> M2fVSlczKGh? MmDS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Ml[2NlQ2QTV{N{S=
MSTO-211H NVzMWnV1S2WubDDWbYFjcWyrdImgRZN{[Xl? NWm4bm52OSCwTT2yNFAh|ryP NVv2elBFPzJiaB?= NWnQNod2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M3K4[|I1PTl3Mke0
MM05 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlvtNUBvVS1{MECg{txO MVS3NkBp M1T3SIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NEnlbmgzPDV7NUK3OC=>
H28 Mo\0R4VtdCCYaXHibYxqfHliQYPzZZk> MXuxJI5ONTJyMDFOwG0> NGLCenk4OiCq NWr0dFR2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVq5S4NVOjR3OUWyO|Q>
SCC25 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfkbZk3NjJ34pETNlAxyqEEtV2= NYnjSnp7PzJiaB?= NXHrR3NbemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36= NHm3VnkzPDV3N{C1Oi=>
CAL27 NEewVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzmOk4zPeLCk{KwNOKhyrWP NYfyNno{PzJiaB?= NGm5ZWhz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= NWizO2E{OjR3NUewOVY>
FaDu  MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHVOk4zPeLCk{KwNOKhyrWP M4DwfVczKGh? NFmwTW9z\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= MojkNlQ2PTdyNU[=
SCC25 NHvURZhCeG:ydH;zbZMhSXO|YYm= MmjoNlXDqML3TdMg M1f6SVQ5yqCqwrC= MlnnbY5lfWOnczDhdI9xfG:|aYO= NWGzU5FROjR3NUewOVY>
CAL27 NWLWeoUzSXCxcITvd4l{KEG|c3H5 MYSyOeKhyrWPwrC= MmXGOFjDqGkEoB?= MUjpcoR2[2W|IHHwc5B1d3Orcx?= NFvzb3gzPDV3N{C1Oi=>
FaDu  NX\QUYhlSXCxcITvd4l{KEG|c3H5 M4HTOVI2yqEEtV5CpC=> M4q4UVQ5yqCqwrC= MVTpcoR2[2W|IHHwc5B1d3Orcx?= MoW1NlQ2PTdyNU[=
T-47D NWC4e2ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSwMVIxKM7:TR?= MY[5OkBp NWXLfW9LcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXjDNpdbOjRzNUOxNFI>
MCF-7  MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HzO|AuOjBizszN MXy5OkBp MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M{nhR|I1OTV|MUCy
T-47D MUPBdI9xfG:|aYOgRZN{[Xl? NGH5XlQxNTJyIN88US=> NXXYVXY1PDhiaB?= MVnpcoR2[2W|IHHwc5B1d3Orcx?= M{TWbFI1OTV|MUCy
MCF-7  MonLRZBweHSxc3nzJGF{e2G7 MUSwMVIxKM7:TR?= NGfGNGk1QCCq M2\aTolv\HWlZYOgZZBweHSxc3nz MkLxNlQyPTNzMEK=
U87MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174bFAuOjVizszN M4rOXVI1NzR6IHi= NYTueJc6cW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NHPWcnkzOzN3NEiwOy=>
U251MG NE\QUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW5OWQ4OC1{NTFOwG0> MXuyOE81QCCq MofnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MmX2NlM{PTR6MEe=
U87MG NVfhboU4SXCxcITvd4l{KEG|c3H5 NWDHNI5wOSEEtV2= Mm\EOFghcA>? MknvbY5lfWOnczDhdI9xfG:|aYO= NWi4NVk{OjN|NUS4NFc>
U251MG MUHBdI9xfG:|aYOgRZN{[Xl? MofHNUDDvU1? MWC0PEBp NWjoeJFCcW6mdXPld{BieG:ydH;zbZM> NES4XmszOzN3NEiwOy=>
U251 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LDSlAuOjVizsznM41N MmfGNE01QCCq MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NXrROHBCOjF5OEizOFM>
U87  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqwMVI2KM7:Zz;tUC=> MYmwMVQ5KGh? NUPMdpYycW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NVHwWYFKOjF5OEizOFM>
U251 NFPpUYRCeG:ydH;zbZMhSXO|YYm= NVXoXXA5OjVizsznM41N Mo\pNlQwPDhiaB?= MVfpcoR2[2W|IHHwc5B1d3OrczDheEA1QCCqIIPp[45q\mmlYX70cJk> M{PveFIyPzh6M{Sz
U87  NVjKUmwySXCxcITvd4l{KEG|c3H5 NXHrSZBROjVizsznM41N NHKyZ5AzPC92ODDo MUXpcoR2[2W|IHHwc5B1d3OrczDheEA1QCCqIIPp[45q\mmlYX70cJk> M1PpU|IyPzh6M{Sz
U251 M2nSUGZ2dmO2aX;uJGF{e2G7 NYTFcYhLOC1{NTFOwIcwdUx? M{fDelEzKGkEoB?= NGjMbmlqdmS3Y3XzJIF2fG:yaHHnfUBld3OnIHTldIVv\GWwdHz5 NGH6OJozOTd6OEO0Ny=>
U87  MlHwSpVv[3Srb36gRZN{[Xl? NFrRPJAxNTJ3IN88[{9uVA>? Mn3GNVIhcMLi MnfXbY5lfWOnczDheZRweGijZ4mg[I9{\SCmZYDlcoRmdnSueR?= M{L6VVIyPzh6M{Sz
U87MG NFTReXpHfW6ldHnvckBCe3OjeR?= NHm3cIgxNjFxMT:xNEDPxE1? M13CUFI1KGh? NULad|ZpcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NXvqRnZDOTl{MkGxO|E>
LN-308 NEHxZ5VHfW6ldHnvckBCe3OjeR?= MYOwMlEwOS9zMDFOwG0> MXGyOEBp M{DQXolueGGrcoOgeIhmKGGmaHXzbY9vKG:oIHPlcIx{KHSxII\peJJwdmWldHnuJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MkjpNVkzOjFzN{G=
LN-18 MnPhSpVv[3Srb36gRZN{[Xl? M1i2elAvOS9zL{GwJO69VQ>? M2jtXlI1KGh? NGe3cppqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MYOxPVIzOTF5MR?=
T98G MYDGeY5kfGmxbjDBd5NigQ>? MUewMlEwOS9zMDFOwG0> MYCyOEBp NIfOcFVqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NV;hPWhOOTl{MkGxO|E>
LNT-229  M{DnVGZ2dmO2aX;uJGF{e2G7 NVPndJhvOC5zL{GvNVAh|ryP NFTVS4MzPCCq NF\5TYpqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MYOxPVIzOTF5MR?=
HMEC-1  NULnVW5ZTnWwY4Tpc44hSXO|YYm= MoH1NU82NzVyIN88[{9udA>? MWqyOEBp MnzTbY5lfWOnczDhJIRwe2ViZHXw[Y5l\W62IHTleIFkcG2nboVCpC=> Mm\MNVkyOTRyMEW=
HMEC-1  MoP0VJJwdGmoZYLheIlwdiCDc4PhfS=> NX33eGFqOS93L{WwJO69\y:vbB?= M1rHR|I1NzR6L{eyJIg> MmGzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWGxPVEyPDByNR?=
HMEC-1  MnPrRZBweHSxc3nzJGF{e2G7 Mle0NU82NzVyIN88[{9udA>? MWKyOEBp M4PXW4lv\HWlZYOgZZBweHSxc3nz MVmxPVEyPDByNR?=
G28 NY\wRYFxWHKxbHnm[ZJifGmxbjDBd5NigQ>? MmHGNU82NzVyIN88[{9udA>? NV\IV2RqOjRxNEivO|IhcA>? NXPjNGNqcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVzGUldsOTlzMUSwNFU>
G44 MlHqVJJwdGmoZYLheIlwdiCDc4PhfS=> NXf3dVhlOS93L{WwJO69\y:vbB?= M3\WO|I1NzR6L{eyJIg> NUTrZotycW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MYKxPVEyPDByNR?=
G28 NHzEXIZCeG:ydH;zbZMhSXO|YYm= MlPmNU82NzVyIN88[{9udA>? M3n2XVI1KGh? NX21VmQxcW6mdXPld{BieG:ydH;zbZM> Mn3vNVkyOTRyMEW=
G44 NFvGS|FCeG:ydH;zbZMhSXO|YYm= MmLINU82NzVyIN88[{9udA>? NGr1SmEzPCCq NX3zR2VWcW6mdXPld{BieG:ydH;zbZM> M1HsZVE6OTF2MEC1
HMEC-1  M1nL[WZ2dmO2aX;uJGF{e2G7 NFnmOZozOC92MD:2NEDPxGdxbXy= MoGybY5pcWKrdIOgSmFMKGGwZDDTdoPDqA>? NYL1emtrOTlzMUSwNFU>
G28 MV;GeY5kfGmxbjDBd5NigQ>? MWq1NEDPxGdxbXy= NYjPVHh[OzBxNkCvNVIxKG2rbh?= MmCxbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGZCUyxiU4LjJIFv\CCDa4S= NHH0dZMyQTFzNECwOS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFAK / p-AKT ; 

PubMed: 19114005     


G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt.

GLI1; 

PubMed: 31366904     


Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs. 

19114005 31366904
Immunofluorescence
VE-cadherin / β3 integrin ; 

PubMed: 19212436     


Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.

19212436
Growth inhibition assay
Cell number ; 

PubMed: 24153102     


Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

24153102
体内研究 Cilengitide单独处理,有效对抗肿瘤生长和血管生成。100 μg Cilengitide处理肿瘤,与对照组相比,显著降低CD31+血管数。100 μg Cilengitide处理动物大脑中的肿瘤,与接收无效肽处理的相比,促进细胞凋亡。Cilengitide 处理携带黑色素移植瘤M21的小鼠,对照组相比,延长小鼠寿命,分别为36.5 天vs 17.3天。[5]Cilengitide 可以增加细胞毒性药物相关联的治疗的益处,包括对肿瘤模型的化疗和放射治疗。Cilengitide (250 mg/dose)单独处理小鼠,与未经处理的小鼠相比,没有改变乳腺癌移植瘤的肿瘤生长,但与RIT(CMRIT)联合治疗,使用RIT和六种剂量的Cilengitide (250 mg/dose)增加治疗的疗效,小鼠的治愈率从只用RIT处理的 15%提高到53%。CMRIT处理内皮细胞5天,显著促进肿瘤细胞凋亡,且降低肿瘤细胞增殖。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
- 合并

整合素竞争结合实验:

固定化重组可溶性的整合素,同时加入在Tris 缓冲生理盐水(TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4)中连续稀释的肽,及生物素化的Vitronectin(1μg/mL)。在37°C下温育3小时后,使用Tris 缓冲生理盐水洗涤,通过与抗生物素的碱性磷酸酶联合的抗体温育,再经对硝基苯基磷酸酶底物显影,测定结合的配体。加入NaOH终止反应,在405 nm处读取彩色信号强度。
细胞实验:[3]
- 合并
  • Cell lines: 人体微血管内皮细胞系HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 天
  • Method: HMEC-1 按每孔1×104个接种在未包被的48孔板中,在含4% FCS 及 Cilengitide的培养基中温育。在37°C下温育72小时, 用胰蛋白酶处理细胞并计数。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 携带人体胶质母细胞瘤移植瘤U87 MG的小鼠
  • Dosages: 100μg
  • Administration: 每天腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 702.68
化学式

C29H41F3N8O9

CAS号 199807-35-7
储存条件 粉状
溶于溶剂
别名 EMD 121974, NSC 707544

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

  • 回答:

    S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

  • 问题 2:

    Is Cilengitide a TFA salt?

  • 回答:

    S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Integrin Signaling Pathway Map

Tags: 购买Cilengitide trifluoroacetate | Cilengitide trifluoroacetate供应商 | 采购Cilengitide trifluoroacetate | Cilengitide trifluoroacetate价格 | Cilengitide trifluoroacetate生产 | 订购Cilengitide trifluoroacetate | Cilengitide trifluoroacetate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID